Wilmington, DE, United States
Wilmington, DE, United States

Incyte is a pharmaceutical company based in Alapocas, Delaware. Incyte has one drug which has been approved by the U.S. Food and Drug Administration and has been prescribed to several thousands of patients in the United States, Jakafi.In 2014, Incyte named Hervé Hoppenot to the posts of President and CEO. Hoppenot had previously served as the President of Novartis Oncology; he had been with Novartis since 2003. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Incyte | Date: 2017-01-18

The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.


The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.


This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3K.


Patent
Incyte | Date: 2017-07-26

The present invention provides heterocyclylamine derivatives of Formula I:


Patent
Incyte | Date: 2017-01-05

The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.


The present invention provides deuterated derivatives of the compounds


The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.


Patent
Incyte | Date: 2017-06-07

The present invention relates to tricyclic compounds of formula (I), and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.


This invention relates to JAK1 selective inhibitors, particularly pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine derivatives, and their use in treating myelodysplastic syndromes (MDS).


Patent
Incyte | Date: 2017-01-17

The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.

Loading Incyte collaborators
Loading Incyte collaborators